# Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

> **NCT05639179** · PHASE1,PHASE2 · UNKNOWN · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 30 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B-ALL

## Interventions

- **BIOLOGICAL:** UCAR-T Cells

## Key facts

- **NCT ID:** NCT05639179
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639179, "Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05639179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*